Differential biomarker responses of hemolysis, inflammation, and myocardial injury after pulsed-field pulmonary vein isolation: balloon-in-basket vs. circular catheter systems - Report - MDSpire

Differential biomarker responses of hemolysis, inflammation, and myocardial injury after pulsed-field pulmonary vein isolation: balloon-in-basket vs. circular catheter systems

  • By

  • Jan-Per Wenzel

  • Raed Abdessadok

  • Charlotte Eitel

  • Sorin Popescu

  • Suzanne de Waha

  • Tanja Zeller

  • Karl-Heinz Kuck

  • Roland Richard Tilz

  • Sascha Hatahet

  • May 29, 2026

  • 0 min

Share

Clinical Report: Comparative Analysis of Biomarker Variations in Hemolysis, Inflammation, and Myocardial Damage Following Pulsed-Field Pulmonary Vein Isolation

Overview

This study compares the biological impact of balloon-in-basket and circular catheter approaches in pulsed-field pulmonary vein isolation (PVI). Both systems induced significant increases in biomarkers of hemolysis, inflammation, and myocardial injury, with notable differences in haptoglobin levels and renal function stability.

Background

Pulsed-field ablation (PFA) is a novel non-thermal technique for pulmonary vein isolation, essential in managing atrial fibrillation (AF). Understanding the systemic effects of different PFA technologies is crucial for optimizing patient outcomes and minimizing complications. This study provides insights into the biomarker responses associated with two distinct PFA catheter designs.

Data Highlights

ParameterBalloon-in-Basket (BiB)Circular Catheter (PS)
Applications Required1632
Contrast Used (mL)4530
Haptoglobin Change (Δ mg/dL)-4-13
Acute Kidney InjuryNo1 Patient

Key Findings

  • Both PFA systems caused significant increases in leukocytes, CRP, LDH, troponin, and CK without inter-group differences.
  • BiB required fewer applications compared to PS (16 vs. 32, p < 0.001).
  • Haptoglobin decreased significantly in both groups, with a more pronounced decline in the PS group (Δ −13 vs. −4 mg/dL, p = 0.090).
  • Renal function remained stable overall, with one PS patient developing acute kidney injury.
  • Δ-Hemoglobin correlated inversely with application number in the BiB group (p = 0.046).
  • Δ-Troponin and Δ-CK correlated positively in the PS group (p < 0.05).

Clinical Implications

Clinicians should be aware of the comparable systemic effects of both PFA systems on biomarkers of hemolysis and myocardial injury. The differences in haptoglobin levels and the isolated acute kidney injury in the PS group may influence catheter selection and patient management strategies during PVI.

Conclusion

This comparative analysis highlights the need for further investigation into the biomarker responses of different PFA technologies. Understanding these differences may enhance clinical decision-making in the treatment of atrial fibrillation.

Related Resources & Content

  1. Clinical Research in Cardiology, 2024 -- Comparative Outcomes at 12 Months for Novel Radiofrequency Balloon and Cryoballoon Technologies in Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
  2. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
  3. Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation, 2023
  4. Volt Pulse Field Ablation (PFA) Clinical Evidence | Abbott
  5. npj Digital Medicine — Development and validation of a machine learning-based scoring system to assess the diagnostic efficacy of endomyocardial biopsy
  6. Basic Research in Cardiology — Effects of Repeated Balloon Inflation During Primary Percutaneous Coronary Intervention on Infarct Size and Long-Term Outcomes in ST-Segment Elevation Myocardial Infarction: Insights from Real-World Postconditioning
  7. Basic Research in Cardiology — In Vivo 19F Cardiovascular Magnetic Resonance Assessment of Inflammation and Contractile Function in Regional Areas Following Reperfused Acute Myocardial Infarction in Porcine Models
  8. Pulsed Field Ablation to Treat Paroxysmal AF - American College of Cardiology
  9. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
  10. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
  11. Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation - Dec 13, 2023
  12. Volt Pulse Field Ablation (PFA) Clinical Evidence | Abbott
  13. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation | New England Journal of Medicine
  14. Characterization and Clinical Significance of Hemolysis After Pulsed Field Ablation for Atrial Fibrillation: Results of a Multicenter Analysis - PubMed
  15. Differential subclinical hemolysis after pulsed field ablation using the FARAPULSE pentaspline catheter vs the PulseSelect circular multi-electrode array catheter - PMC
  16. Inflammation and myocardial injury after pulmonary vein isolation with distinct pulsed field ablation modalities: Comparison with thermal ablation - ScienceDirect
  17. A comparative analysis of postprocedural troponin levels and the impact of renal impairment in patients undergoing pulmonary vein isolation: pulsed field ablation vs. radiofrequency ablation | European Journal of Medical Research | Full Text

Original Source(s)

Related Content